- Report
- March 2024
- 191 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- March 2024
- 257 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Clinical Trials
- November 2022
- 80 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- May 2021
- 50 Pages
China
From €2510EUR$2,600USD£2,153GBP
- Report
- July 2020
- 1740 Pages
Global
From €4633EUR$4,800USD£3,974GBP
- Report
- July 2018
- 175 Pages
Global
From €21234EUR$22,000USD£18,215GBP
- Report
- February 2024
- 73 Pages
Global
From €3500EUR$3,884USD£3,107GBP
- Report
- January 2021
- 140 Pages
China, Global
From €3000EUR$3,330USD£2,663GBP
- Report
- April 2024
- 50 Pages
Global
From €2558EUR$2,650USD£2,194GBP
Dasatinib is a type of leukemia drug used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Dasatinib is typically used in combination with other drugs to treat CML and Ph+ ALL. It is also used to treat other types of leukemia, such as myelodysplastic syndrome (MDS) and myelofibrosis.
Dasatinib is available in both oral and intravenous formulations. It is typically prescribed as a first-line treatment for CML and Ph+ ALL, and is often used in combination with other drugs. Common side effects of dasatinib include nausea, vomiting, diarrhea, fatigue, and headache.
Some companies in the dasatinib market include Bristol-Myers Squibb, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more
